Harvard Bioscience (HBIO) Gross Profit (2010 - 2026)

Harvard Bioscience (HBIO) has reported Gross Profit for 17 consecutive years, with $12.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit changed 0.49% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $50.0 million (down 4.23% YoY), while the FY2025 annual figure was $49.9 million, down 8.87% from the prior year.
• Gross Profit slipped to $12.2 million in Q1 2026 per HBIO's latest filing, from $14.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $18.3 million in Q1 2023 and bottomed at $11.5 million in Q2 2025.
• Historically, Gross Profit has averaged $14.3 million across 5 years, with a median of $14.2 million in 2025.
• Annual changes were most pronounced in 2022 — Gross Profit slipped 25.36% — and 2023, when it advanced 20.99%.
• Harvard Bioscience's Gross Profit stood at $15.8 million in 2022, then rose by 3.11% to $16.3 million in 2023, then decreased by 14.17% to $14.0 million in 2024, then grew by 1.15% to $14.2 million in 2025, then fell by 13.6% to $12.2 million in 2026.
• Business Quant data shows HBIO's Gross Profit at $12.2 million in Q1 2026, $14.2 million in Q4 2025, and $12.0 million in Q3 2025.